Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS OTCMKTS:ALSE OTCMKTS:AOLS OTCMKTS:RCDTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00+900.0%$0.00$0.00▼$0.00N/A-1.85N/A200 shsALSEAlseres Pharmaceuticals$0.01$0.01$0.01▼$0.01N/AN/AN/AN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.37N/AN/ARCDTFRecordati Industria Chimica E Farmaceutica$65.44$65.44$49.00▼$65.44N/A0.191 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ALSEAlseres Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%RCDTFRecordati Industria Chimica E Farmaceutica0.00%0.00%0.00%+16.77%+25.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00+900.0%$0.00$0.00▼$0.00N/A-1.85N/A200 shsALSEAlseres Pharmaceuticals$0.01$0.01$0.01▼$0.01N/AN/AN/AN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.37N/AN/ARCDTFRecordati Industria Chimica E Farmaceutica$65.44$65.44$49.00▼$65.44N/A0.191 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ALSEAlseres Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%RCDTFRecordati Industria Chimica E Farmaceutica0.00%0.00%0.00%+16.77%+25.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AALSEAlseres Pharmaceuticals 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/ARCDTFRecordati Industria Chimica E Farmaceutica 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest RCDTF, ACUS, AOLS, and ALSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025RCDTFRecordati Industria Chimica E FarmaceuticaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/ARCDTFRecordati Industria Chimica E Farmaceutica$2.53BN/A$3.06 per share21.39N/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00∞N/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ARCDTFRecordati Industria Chimica E Farmaceutica$450.70M$2.0032.72∞N/AN/AN/AN/A11/11/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/ARCDTFRecordati Industria Chimica E FarmaceuticaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/ARCDTFRecordati Industria Chimica E Farmaceutica1.041.591.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AALSEAlseres PharmaceuticalsN/AAOLSAeolus PharmaceuticalsN/ARCDTFRecordati Industria Chimica E FarmaceuticaN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ALSEAlseres Pharmaceuticals8.94%AOLSAeolus Pharmaceuticals66.60%RCDTFRecordati Industria Chimica E FarmaceuticaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableALSEAlseres Pharmaceuticals3N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionableRCDTFRecordati Industria Chimica E Farmaceutica4,583N/AN/ANot OptionableRCDTF, ACUS, AOLS, and ALSE HeadlinesRecent News About These CompaniesEuropean Stocks Estimated To Be Undervalued In August 2025August 22, 2025 | finance.yahoo.comRecordati e Amarin, accordo per Vazkepa in 59 PaesiJune 29, 2025 | farmaciavirtuale.itFGrey firma il nuovo spot Recordati per EumillJune 23, 2025 | engage.itEPiazza Affari: performance negativa per RecordatiJune 18, 2025 | teleborsa.itTPiazza Affari ultime previsioni titoli: Unicredit, Prysmian, RecordatiJune 11, 2025 | fxempire.itFAzioni Recordati: valore giusto è 67 euro? E’ corsa a comprareJune 6, 2025 | borsainside.comBRecordati in pole nel FTSE MIB, assist da analistiJune 6, 2025 | teleborsa.itTRecordati, JP Morgan alza il target priceJune 6, 2025 | soldionline.itSBorsa Italiana previsioni 3 azioni: Stellantis, Recordati, Banca GeneraliJune 6, 2025 | fxempire.itFRecordati brilla grazie alla promozione di Jp MorganJune 6, 2025 | ilsole24ore.comIRecordati, JP Morgan alza il prezzo obiettivo dopo la trimestraleJune 6, 2025 | soldionline.itSRecordati prosegue il buyback e raggiunge l'1,6% del capitale socialeJune 5, 2025 | teleborsa.itTAcquisti su Recordati. Settore biotech in fermento dopo le ultime operazioni di M&AJune 3, 2025 | ilsole24ore.comIDrug maker Recordati's Q1 revenue rises 11.9%, confirms 2025 guidanceMay 9, 2025 | msn.comRecordati, ricavi ed EBITDA in crescita a doppia cifra nel primo trimestreMay 8, 2025 | teleborsa.itTRecordati stock rises following 1Q earnings beatMay 8, 2025 | investing.comRecordati, la cassa balza a 158 milioni e il debito cala a 2 miliardiMay 8, 2025 | msn.comCampari e Recordati si Staccano dal FTSE MIBMay 3, 2025 | fxempire.itFPrevisioni azioni industriali Italia: Buzzi, Recordati, STMicroelectronicsApril 30, 2025 | fxempire.itFItaly’s Recordati Sees Tariff Volatility Fueling DealmakingApril 30, 2025 | livemint.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCDTF, ACUS, AOLS, and ALSE Company DescriptionsAcusphere OTCMKTS:ACUS$0.0010 +0.00 (+900.00%) As of 09/5/2025 05:20 PM EasternAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.Alseres Pharmaceuticals OTCMKTS:ALSE$0.0050 0.00 (0.00%) As of 10/18/2024Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF$65.44 0.00 (0.00%) As of 09/5/2025Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
